Voluntary announcement - completion of all subjects enrollment in the phase iii registrational clinical trial of TQC3721 inhalation suspension "PDE3/4 inhibitor"
Filed with HKEX · Stock code 1177 · · 2 pages · English
Summary by 6ix AI
This innovative drug aims to improve ventilation and control inflammation in patients suffering from COPD, which is a significant global health issue. The trial's completion marks a critical step towards potentially introducing a new treatment option for COPD patients in China.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
(Incorporated in the Cayman Islands with limited liability) Website: www.sbpgroup.com (Stock code: 1177) VOLUNTARY ANNOUNCEMENT ## COMPLETION OF ALL SUBJECTS ENROLLMENT IN THE PHASE III ## REGISTRATIONAL CLINICAL TRIAL OF TQC3721 INHALATION SUSPENSION “PDE3/4 INHIBITOR” The board of directors (the “Board”) of Sino Biopharmaceutical Limited (the “Company”, together with its subsidiaries, the “Group
Sino Biopharmaceutical Limited on 6ix
Earlier from Sino Biopharmaceutical
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - enter into strategic biosimilars partnership with stada
- Notification letter and request form for non-registered shareholders
- Notification letter and reply form for registered shareholders
- 2026 Interim report
Later from Sino Biopharmaceutical
- Next day disclosure return
- Voluntary announcement - latest research results on tq-A3334 "TLR7 agonist" and bepirovirsen "aso" to be presented at 2026 aasld
Follow Sino Biopharmaceutical into a list and get an email when it puts out news.
Follow Sino Biopharmaceutical